AstraZeneca PLC (AZN.ST)
- Previous Close
1,497.00 - Open
1,497.00 - Bid --
- Ask --
- Day's Range
1,494.00 - 1,504.00 - 52 Week Range
1,261.00 - 1,616.00 - Volume
4,550 - Avg. Volume
332,556 - Market Cap (intraday)
2.325T - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
35.91 - EPS (TTM)
41.77 - Earnings Date --
- Forward Dividend & Yield 30.74 (2.05%)
- Ex-Dividend Date Feb 22, 2024
- 1y Target Est
1,163.40
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
www.astrazeneca.com89,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AZN.ST
Performance Overview: AZN.ST
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZN.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZN.ST
Valuation Measures
Market Cap
2.31T
Enterprise Value
2.56T
Trailing P/E
35.89
Forward P/E
16.23
PEG Ratio (5yr expected)
0.87
Price/Sales (ttm)
4.66
Price/Book (mrq)
5.42
Enterprise Value/Revenue
55.79
Enterprise Value/EBITDA
190.41
Financial Highlights
Profitability and Income Statement
Profit Margin
13.00%
Return on Assets (ttm)
6.60%
Return on Equity (ttm)
15.64%
Revenue (ttm)
45.81B
Net Income Avi to Common (ttm)
5.95B
Diluted EPS (ttm)
41.77
Balance Sheet and Cash Flow
Total Cash (mrq)
5.86B
Total Debt/Equity (mrq)
75.70%
Levered Free Cash Flow (ttm)
9.5B